FRX has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
GuruFocus Financial Strength Rank measures how strong a companys financial situation is. It is based on these factors
1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.
A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.
1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank
|Louis Moore Bacon 15,810 sh (New)|
Jim Simons 834,300 sh (+18.36%)
|First Eagle Investment 806,230 sh (unchged)|
Bernard Horn 62,200 sh (unchged)
|Carl Icahn Sold Out|
Joel Greenblatt Sold Out
Paul Tudor Jones Sold Out
Bill Nygren Sold Out
Murray Stahl Sold Out
Vanguard Health Care Fund 15,716,666 sh (-23.65%)
Mario Gabelli 183,200 sh (-26.04%)
Jeremy Grantham 170,000 sh (-32.54%)
Dodge & Cox 45,100 sh (-98.84%)
(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)
|Short Percentage of Float||1.88%|
|52-Week Range $||40.98 - 100.88|
|Industry:||Drug Manufacturers » Drug Manufacturers - Specialty & Generic|
|Compare:||TKPYY, TEVA, AGN, MRX, ESALF » details|
|Traded in other countries:||FQX.Germany,|
|Forest Laboratories, Inc. is a Delaware corporation organized in 1956. The Company develops, manufactures and sells branded forms of ethical drug products most of which require a physician's prescription. The Company's most important United States products are marketed directly, or 'detailed,' to physicians by its salesforces. It emphasizes detailing to physicians of those branded ethical drugs which have the most potential for growth and benefit to patients. The Company also develops and introduces new products, including products developed in collaboration with licensing partners. The Company's products include those developed by it and those acquired from other pharmaceutical companies and integrated into its marketing and distribution systems. It actively promotes in the United States those branded products which have the most potential for growth and patient benefit, and which enable its salesforces to concentrate on groups of physicians who are high prescribers of its products. Such products include: Lexapro, its SSRI for the treatment of major depression in adults and adolescents and GAD in adults; Namenda, its NMDA antagonist for the treatment of moderate and severe Alzheimer's disease; Bystolic, its beta-blocker for the treatment of hypertension; and Savella, its newest product, an SNRI for the management of fibromyalgia. The Company's United Kingdom and Ireland subsidiaries sell both ethical products and over-the-counter preparations. Their most important products include Sudocrem, a topical preparation for the treatment of diaper rash; Colomycin, an antibiotic used in the treatment of cystic fibrosis; Infacol, used to treat infant colic; and Exorex, used in the treatment of eczema and psoriasis. The pharmaceutical industry is subject to comprehensive government regulation which substantially increases the difficulty and cost incurred in obtaining the approval to market newly proposed drug products and maintaining the approval to market existing drugs.|
|Carl Icahn Turns Up Pressure on AIG, May Propose New Leadership Nov 23 2015|
|Bill Nygren's Fourth Quarter Commentary – Oakmark Fund Jan 09 2015|
|Bill Nygren’s 4Q 2014 Market Commentary Jan 08 2015|
|Bernard Horn Comments on Forest Laboratories Aug 26 2014|
|Bernard Horn’s Polaris Global Value Fund 2Q 2014 Message to Our Shareholders Aug 26 2014|
|Global Guru Bernard Horn Reports his Top Five from the Second Quarter Aug 22 2014|
|Guru of the Year – Carl Icahn’s Top Five Holdings Aug 17 2014|
|Bernard Horn Comments on Forest Laboratories Aug 07 2014|
|Diamond Hill Capital Comments on Forest Laboratories Inc Jun 26 2014|
|GuruFocus Guru of the 2013 Carl Icahn's Top First Quarter Holdings May 15 2014|